{
    "ticker": "CRML",
    "name": "Cerus Corporation",
    "description": "Cerus Corporation is a biomedical company focused on the development and commercialization of the INTERCEPT Blood System, a revolutionary approach designed to enhance the safety of blood transfusions. Founded in 1991 and headquartered in Concord, California, Cerus aims to improve transfusion medicine by providing innovative technologies that reduce the risk of transfusion-transmitted infections. The INTERCEPT Blood System employs a novel pathogen inactivation method that uses a proprietary technology to effectively eliminate viruses, bacteria, and parasites from donated blood products while preserving the integrity of the blood components. Cerus is committed to addressing the needs of healthcare systems and patients worldwide, ensuring that blood transfusions are as safe as possible. The company partners with blood centers and hospitals globally, striving to improve patient outcomes through enhanced blood safety protocols. As the demand for safe blood products continues to grow, Cerus is well-positioned to lead the market with its cutting-edge solutions. The company is also focused on expanding its product offerings and applications, with ongoing research and development efforts aimed at introducing new technologies to further enhance blood safety and efficacy.",
    "industry": [
        "Biotechnology",
        "Medical Devices"
    ],
    "headquarters": "Concord, California, USA",
    "founded": "1991",
    "website": "https://www.cerus.com",
    "ceo": "William 'Bill' Greenman",
    "social_media": {
        "twitter": "https://twitter.com/CerusCorp",
        "linkedin": "https://www.linkedin.com/company/cerus-corporation/"
    },
    "investor_relations": "https://investors.cerus.com",
    "key_executives": [
        {
            "name": "William Greenman",
            "position": "CEO"
        },
        {
            "name": "Kevin D. G. R. O'Connell",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Blood Safety Products",
            "products": [
                "INTERCEPT Blood System for Platelets",
                "INTERCEPT Blood System for Plasma",
                "INTERCEPT Blood System for Red Blood Cells"
            ]
        }
    ],
    "seo": {
        "meta_title": "Cerus Corporation | Innovating Blood Safety Solutions",
        "meta_description": "Discover Cerus Corporation, a leader in blood safety technology with the INTERCEPT Blood System. Learn about our commitment to improving transfusion safety worldwide.",
        "keywords": [
            "Cerus Corporation",
            "Blood Safety",
            "INTERCEPT Blood System",
            "Medical Technology",
            "Transfusion Medicine"
        ]
    },
    "faq": [
        {
            "question": "What is Cerus Corporation known for?",
            "answer": "Cerus Corporation is known for its INTERCEPT Blood System, which enhances the safety of blood transfusions by eliminating pathogens."
        },
        {
            "question": "Who is the CEO of Cerus Corporation?",
            "answer": "William Greenman is the CEO of Cerus Corporation."
        },
        {
            "question": "Where is Cerus Corporation headquartered?",
            "answer": "Cerus Corporation is headquartered in Concord, California, USA."
        },
        {
            "question": "What are the main products of Cerus Corporation?",
            "answer": "Cerus Corporation's main products include the INTERCEPT Blood System for Platelets, Plasma, and Red Blood Cells."
        },
        {
            "question": "When was Cerus Corporation founded?",
            "answer": "Cerus Corporation was founded in 1991."
        }
    ],
    "competitors": [
        "BLRX",
        "XLRN",
        "ADMA"
    ],
    "related_stocks": [
        "ABT",
        "BMY",
        "JNJ",
        "MDT"
    ]
}